Viking Therapeutics Files 8-K on Financials
Ticker: VKTX · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1607678
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) filed an 8-K on Feb 5, 2025, updating on financials. No major news yet.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on February 5, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing does not contain specific financial figures or operational updates but serves as a notification of these reporting items.
Why It Matters
This filing indicates that Viking Therapeutics is providing updates on its financial condition and results of operations, which are crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and exhibits, not announcing new material events or significant financial changes.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121 (address) — Principal Executive Offices
- 858-704-4660 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details of the financial information are not provided in the provided text.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 5, 2025.
What is the principal executive office address for Viking Therapeutics, Inc.?
The principal executive office address is 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
In which state was Viking Therapeutics, Inc. incorporated?
Viking Therapeutics, Inc. was incorporated in Delaware.
What is the purpose of this Form 8-K filing for Viking Therapeutics, Inc.?
The purpose of this Form 8-K filing is to report on the 'Results of Operations and Financial Condition' and to include 'Financial Statements and Exhibits'.
Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-02-05 16:07:52
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20250205.htm (8-K) — 47KB
- vktx-ex99_1.htm (EX-99.1) — 266KB
- img201808844_0.jpg (GRAPHIC) — 13KB
- 0000950170-25-014464.txt ( ) — 469KB
- vktx-20250205.xsd (EX-101.SCH) — 30KB
- vktx-20250205_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 5, 2025, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2024 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press release issued February 5, 2025, reporting financial results for the fourth quarter and year ended December 31, 2024 and providing a corporate update. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viking Therapeutics, Inc. Date: February 5, 2025 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)